Beta-Blockers
Key Points
- Beta-blockers (beta-adrenergic blockers) block beta-1 and/or beta-2 receptors, decreasing heart rate, myocardial contractility, and blood pressure.
- Cardioselective beta-1 blockers (metoprolol, atenolol) primarily affect the heart; nonselective (propranolol, carvedilol) also affect lungs and peripheral vasculature.
- Hold dose and notify provider if heart rate <60 beats/minute or blood pressure is critically low before administration.
- Abrupt discontinuation is dangerous — always taper over 1–2 weeks to prevent rebound tachycardia, arrhythmias, angina, or MI.
- Key hazard: mask hypoglycemia symptoms in diabetic patients — monitor blood glucose carefully.
- IV esmolol is a short-acting, titratable beta-1 blocker for acute rate control and requires close blood-pressure monitoring.
- In HF patients with asthma or bronchoconstrictive disease, nonselective agents (for example carvedilol) require cautious lung assessment because bronchospasm risk is higher.
- Beta-blocker off-label anxiolytic use requires explicit risk-benefit review because this indication is not FDA-approved.
- In heart-failure pathways, bisoprolol, metoprolol succinate, and carvedilol are common mortality-reduction selections.
- After MI, continuing beta-blocker therapy in recovery pathways helps reduce reinfarction risk.
- Ophthalmic timolol can still produce systemic beta-blockade effects; punctal occlusion after instillation helps reduce systemic absorption.
Mechanism of Action
Beta-blockers competitively inhibit catecholamines (epinephrine, norepinephrine) at adrenergic receptor sites:
| Receptor | Location | Effect of Blockade |
|---|---|---|
| Beta-1 | Heart, kidneys | ↓ Heart rate, ↓ myocardial contractility, ↓ renin release → ↓ blood pressure |
| Beta-2 | Lungs, peripheral vasculature | Bronchoconstriction, peripheral vasoconstriction (nonselective agents) |
Cardioselective agents (metoprolol, atenolol) primarily block beta-1 receptors — safer in pulmonary disease but bronchoconstriction still possible at higher doses.
Common Beta-Blockers
| Drug | Selectivity | Routes | Common Indication |
|---|---|---|---|
| Esmolol (Brevibloc) | Beta-1 selective | IV infusion | Short-term acute rate control (for example AF with rapid ventricular response), perioperative tachycardia/HTN; rapid onset and very short half-life |
| Metoprolol tartrate (Lopressor) | Beta-1 selective | PO, IV | Hypertension, MI, heart-failure (heart failure); IV pathways may use 5 mg slow push over 1-2 minutes and repeat dosing per protocol/order |
| Metoprolol succinate (Toprol-XL) | Beta-1 selective | PO (extended-release) | Heart failure, hypertension |
| Atenolol (Tenormin) | Beta-1 selective | PO | Hypertension, angina |
| Carvedilol (Coreg) | Nonselective + alpha | PO | Heart failure, hypertension |
| Propranolol (Inderal) | Nonselective | PO, IV | Dysrhythmias, migraine (migraine), anxiety/panic-autonomic symptoms, hypertension |
| Labetalol | Nonselective + alpha | PO, IV | Hypertensive emergencies, pregnancy-related hypertension |
Indications
- Hypertension (first-line or adjunct)
- Heart failure (carvedilol, metoprolol succinate — reduce mortality)
- Angina and coronary artery disease
- Dysrhythmias: rate control in atrial fibrillation, supraventricular tachycardia
- Acute myocardial infarction — reduce cardiac workload and infarct size
- Migraine prophylaxis, essential tremor (propranolol), anxiety (off-label)
Nursing Assessment
NCLEX Focus
Always assess apical heart rate AND blood pressure before administering any beta-blocker. When no other parameters are provided, hold if HR <60 bpm or SBP <100 mm Hg and contact provider before giving the dose.
Pre-administration:
- Obtain apical heart rate and blood pressure — hold if HR <60 bpm or per facility protocol
- Many HF protocols use a hold range threshold near HR <50-60 bpm; follow the active order set and escalate uncertainty before dosing.
- If order-specific parameters are absent, use conservative safety hold thresholds (for example HR <60 bpm or SBP <100 mm Hg) and escalate to provider.
- In severe bradycardia without a functioning pacemaker, withhold and escalate before administration.
- Assess for contraindications: active bronchospasm, decompensated heart failure, severe bradycardia, AV block
- Review diabetes status — beta-blockers mask sympathetic signs of hypoglycemia (tachycardia, tremor)
- For ophthalmic timolol/betaxolol, monitor for bradycardia, hypotension, dyspnea/bronchospasm, and reinforce medial-canthus pressure after drops.
- For propranolol, assess pulmonary history carefully (asthma/COPD bronchoconstriction risk) and hepatic/renal function trend.
- In clients with asthma/COPD using short-acting beta agonists (SABAs), verify bronchodilator-response risk because beta-blockers can reduce SABA effect.
- For IV metoprolol, anticipate rapid onset (about 5 minutes), peak effect around 15-30 minutes, and duration near 3-6 hours; plan near-term reassessment windows accordingly.
- In acute-MI pathways, common hold/escalation thresholds are symptomatic bradycardia (often below about 50 bpm) or hypotension (for example below about 90/50 mm Hg), unless provider-specific parameters differ.
Contraindications:
- Moderate to severe asthma or COPD (especially nonselective agents — bronchoconstriction risk)
- Bradycardia (HR <60 bpm), second or third-degree AV block
- Cardiogenic shock, decompensated acute heart failure
- Sick sinus syndrome without pacemaker
Nursing Interventions
- Administer extended-release formulations intact — do not crush or split (Toprol-XL, Coreg CR)
- Do not confuse metoprolol tartrate (immediate release) with metoprolol succinate (extended release); they are not directly interchangeable by schedule.
- For propranolol, give immediate-release formulations on an empty stomach and avoid simple milligram-for-milligram substitution between ER and conventional formulations.
- Monitor blood pressure and heart rate regularly; educate client on self-monitoring technique
- Monitor blood glucose in diabetic clients — adrenergic signs of hypoglycemia are blunted
- During IV administration, monitor heart rate, blood pressure, and ECG rhythm closely for bradycardia, hypotension, or conduction worsening.
- For esmolol infusion, monitor IV site closely because extravasation can cause tissue injury; if suspected, stop infusion, aspirate line if possible, and elevate affected limb per policy.
- Reconcile interaction risk before dosing: albuterol/SABA therapies, clonidine, fluoxetine, paroxetine, quinidine, propafenone, mefloquine, and stimulant/depressant OTC products.
Adverse effects to monitor:
- Bradycardia and hypotension — most serious cardiovascular adverse effects
- Fatigue, dizziness, orthostatic hypotension
- Bronchoconstriction (especially nonselective agents — monitor breath sounds)
- Cold extremities (peripheral vasoconstriction)
- Increased sensitivity to cold exposure
- Raynaud-phenomenon worsening or new vasospastic peripheral symptoms
- Depression, insomnia, nightmares (CNS effects)
- Masking of hypoglycemia symptoms in diabetes
Abrupt Discontinuation Risk
Beta-blockers must never be stopped abruptly. Rebound hypertension, unstable angina, or acute MI can result. Taper the dose over 1–2 weeks under provider supervision when discontinuing therapy.
Patient education:
- Take at the same time each day; never skip or suddenly stop taking
- Report dizziness, severe fatigue, or shortness of breath to provider
- Use caution with position changes — orthostatic hypotension
- Avoid caffeine and alcohol (increase cardiovascular stress)
- Avoid tobacco and licorice excess that can destabilize blood-pressure control
- Avoid OTC/herbal combinations without pharmacist or prescriber review, especially ma-huang/ephedra, black cohosh, hawthorn, and concentrated licorice products.
- Diabetic clients: monitor blood glucose more frequently; rely on glucose readings rather than symptoms to detect hypoglycemia
- Inform dentists and other providers of beta-blocker use before procedures
Related Concepts
- cardiovascular-system — Heart rate and contractility regulation affected by beta-receptor blockade.
- hypertension-assessment-and-management — Beta-blockers as first-line or adjunct antihypertensive agents.
- heart-failure — Carvedilol and metoprolol succinate as evidence-based heart failure therapies.
- systematic-ecg-interpretation-and-dysrhythmia-triage — Beta-blockers for rate control in atrial fibrillation and supraventricular tachycardia.
- diabetes-mellitus — Risk of masked hypoglycemia symptoms in diabetic patients on beta-blockers.
- high-alert-medications — Beta-blockers as medications requiring pre-dose vital sign assessment.
- antiglaucoma-medications — Ophthalmic beta-blocker role in intraocular-pressure reduction.
Self-Check
- A client with hypertension and type 2 diabetes is started on metoprolol. What specific monitoring is required, and why?
- Before administering metoprolol 25 mg PO, the nurse assesses an apical heart rate of 54 bpm. What is the appropriate nursing action?
- A client asks why they cannot stop taking their beta-blocker suddenly. What is the evidence-based explanation?